Apple: Analysts' Upgrades, Downgrades

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Amylin Pharmaceuticals (AMLN) upgraded at Citigroup from Hold to Buy. $27 price target. Remain optimistic that the FDA will ultimately approve LAR.

Amylin Pharmaceuticals (AMLN) price target raised at Barclays $2 to $24 on approval of drug Victoza. 2009 and 2010 EPS estimates set at -$1.25 and -$0.35, respectively. Maintain Overweight rating.

Arena Resources (symbol) upgraded at UBS from Neutral to Buy. $46 price target. Stock is down 10% year-to-date, but should exceed better-than-expected production growth.

Anixter (AXE) downgraded at Credit Suisse to Underperform from Neutral as underlying business is flat, and earnings expectations are weak. $36 price target. 2009 and 2010 EPS estimates set at $2.27 and $2.84, respectively.

Continental Resources (CLR) upgraded at UBS from Neutral to Buy. $46 price target. Valuation call, as the stock is down 15% in recent weeks. Company also has a strong balance sheet.

Celestica (CLS) upgraded at Credit Suisse to Outperform from Neutral as checks suggest near-term and long-term trends are improving. Company has excess cash. Price target jumped to $11.50 from $9.50.

CNX Gas (CXG) upgraded at UBS from Neutral to Buy. $34 price target. Reserves are up 34% year-over-year.

Crimson Exploration (CXPO) initiated at Barclays with an Overweight rating and $8 price target. Drilling results in the Haynesville Shale will drive shares. 2009 and 2010 EPS estimates set at -$1.45 and -$0.20, respectively.

Eaton (ETN) target, estimate raised at Barclays. Barclays increased ETN price target to $69 from $62 after 4Q09 results beat. 2010 EPS estimate lifted to $4.05 from $3.55. Maintain Equal Weight rating.